

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION No. 1921
TO BE ANSWERED ON THE 02ND AUGUST, 2024

Promotion of Domestic Manufacturing of Medicines

1921 Shri Vishnu Datt Sharma:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Government is making efforts to promote domestic manufacturing of medicines for rare genetic disorders considering their scarce availability and prohibitive cost in the country;
- (b) if so, the details of the efforts made and outcomes achieved in this regard; and
- (c) if not, the reasons therefor?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS &
FERTILIZERS**

(SMT. ANUPRIYA PATEL)

(a) to (c): The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:

S. No.	Name of the product	Usage
1	Nitisinone	Treatment of Hereditary Tyrosinemia Type 1
2	Nusinersen	Treatment of Spinal Muscular Atrophy
3	Rufinamide	Treatment of Lennox-Gastaut syndrome.
4	Sodium Phenyl Butyrate	Treatment of Urea Cycle Disorders
5	Tiopronin	Prevention of Cystine Nephrolithiasis
6	Trientine Hydrochloride	Treatment of Wilson's disease
7	Eliglustat	Treatment of Gaucher's disease
8	Cannabidiol	Treatment of Dravet-Lennox Gastaut syndrome
